Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections
Status:
Unknown status
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
to assess the efficacy and safety of recombinant human interferon α-2b gel (Yallaferon®) for
the treatment of patients with cervical HPV-16 and/or HPV-18 infections; to analyze the HPV
type infections and clinical negative conversion.